Login Register Cart 0
Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Automating Drug Discovery using Machine Learning

Author(s): Ali K. Abdul Raheem* and Ban N. Dhannoon

Volume 20, Issue 6, 2023

Published on: 13 July, 2023

Article ID: e070623217776 Pages: 8

DOI: 10.2174/1570163820666230607163313

Price: $65

Abstract

Drug discovery and development have been sped up because of the advances in computational science. In both industry and academics, artificial intelligence (AI) has been widely used. Machine learning (ML), an important component of AI, has been used in a variety of domains, including data production and analytics. One area that stands to gain significantly from this achievement of machine learning is drug discovery. The process of bringing a new drug to market is complicated and time-consuming. Traditional drug research takes a long time, costs a lot of money, and has a high failure rate. Scientists test millions of compounds, but only a small number make it to preclinical or clinical testing. It is crucial to embrace innovation, especially automated technologies, to lessen the complexity involved in drug research and avoid the high cost and lengthy process of bringing a medicine to the market. A rapidly developing field, a branch of artificial intelligence called machine learning (ML), is being used by numerous pharmaceutical businesses. Automating repetitive data processing and analysis processes can be achieved by incorporating ML methods into the drug development process. ML techniques can be used at numerous stages of the drug discovery process. In this study, we will discuss the steps of drug discovery and methods of machine learning that can be applied in these steps, as well as give an overview of each of the research works in this field.

Graphical Abstract

[1]
Patel L, Shukla T, Huang X, Ussery DW, Wang S. Machine Learning Methods in Drug Discovery. Molecules 2020; 25(22): 5277.
[http://dx.doi.org/10.3390/molecules25225277] [PMID: 33198233]
[2]
Wishart DS. Introduction to Cheminformatics. Curr Protoc Bioinformatics. 2007. Chapter 14: Unit 14.1
[http://dx.doi.org/10.1002/0471250953.bi1401s18]
[3]
U.S. Food and Drug Administration 2018 The drug development process. Available from:https://www.fda.gov/patients/drug-development-process/step-3-clinical-research
[4]
Helleboid S, Haug C, Lamottke K, et al. The identification of naturally occurring neoruscogenin as a bioavailable, potent, and high-affinity agonist of the nuclear receptor RORα (NR1F1). SLAS Discov 2014; 19(3): 399-406.
[http://dx.doi.org/10.1177/1087057113497095] [PMID: 23896689]
[5]
2018.https://www.fda.gov/patients/drug-development-process/step-3-clinical-research
[6]
Duelen R, Corvelyn M, Tortorella I, Leonardi L, Chai Y, Sampaolesi M. Medicinal Biotechnology for Disease Modeling, Clinical Therapy, and Drug Discovery and DevelopmentIntroduction to Biotech Entrepreneurship: From Idea to Business. Cham: Springer 2019.
[http://dx.doi.org/10.1007/978-3-030-22141-6_5]
[7]
David L, Thakkar A, Mercado R, Engkvist O. Molecular representations in AI-driven drug discovery: A review and practical guide. J Cheminform 2020; 12(1): 56.
[http://dx.doi.org/10.1186/s13321-020-00460-5] [PMID: 33431035]
[8]
Capecchi A, Probst D, Reymond JL. One molecular fingerprint to rule them all: Drugs, biomolecules, and the metabolome. J Cheminform 2020; 12(1): 43.
[http://dx.doi.org/10.1186/s13321-020-00445-4] [PMID: 33431010]
[9]
Mitchell T. Machine Learning. New York: McGraw Hill 1997.
[10]
Rohall SL, Auch L, Gable J, et al. An artificial intelligence approach to proactively inspire drug discovery with recommendations. J Med Chem 2020; 63(16): 8824-34.
[http://dx.doi.org/10.1021/acs.jmedchem.9b02130] [PMID: 32101427]
[11]
Elbadawi M, Muñiz Castro B, Gavins FKH, et al. M3DISEEN: A novel machine learning approach for predicting the 3D printability of medicines. Int J Pharm 2020; 590: 119837.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119837] [PMID: 32961295]
[12]
Ekins S, Puhl AC, Zorn KM. A decade of progress in pharmaceutical machine learning. Nat Rev Drug Discov 2019; 18(7): 527-31.
[http://dx.doi.org/10.1038/d41573-019-00007-6] [PMID: 30867601]
[13]
Lavecchia A. Machine-learning approaches in drug discovery: Methods and applications. Drug Discov Today 2019; 24(3): 750-9.
[http://dx.doi.org/10.1016/j.drudis.2018.12.039] [PMID: 25448759]
[14]
Ma J, Sheridan RP. LiSiCA: A software for ligand-based virtual screening using a consensus scoring strategy. J Chem Inf Model 2019; 59(2): 614-20.
[http://dx.doi.org/10.1021/acs.jcim.8b00768]
[15]
Schwaller P, Laino T, Gaudin T, et al. Molecular machine learning with Python. Chem Sci (Camb) 2020; 11(36): 9450-67.
[http://dx.doi.org/10.1039/d0sc02203e]
[16]
Abdul Raheem K, Ali S, Dhannoon BN. Predication and Classification of Cancer Using Sequence Alignment and Back Propagation Algorithms in Brca1 and Brca2 Genes. International Journal of Pharmaceutical Research 2019; 11(1): 62-70.
[http://dx.doi.org/10.31838/ijpr/2019.11.01.062]
[17]
Lee CY, Chen YPP. Descriptive prediction of drug side‐effects using a hybrid deep learning model. Int J Intell Syst 2021; 36(6): 2491-510.
[http://dx.doi.org/10.1002/int.22389]
[18]
Shim J, Hong ZY, Sohn I, Hwang C, Kim S. Prediction of drug–target binding affinity using similarity-based convolutional neural network. Sci Rep 2021; 11(1): 4416.
[http://dx.doi.org/10.1038/s41598-021-83679-y] [PMID: 33627791]
[19]
Hu S, Zhang C, Chen P, Jiang Y. Predicting drug-target interactions from drug structure and protein sequence using novel convolutional neural networks. BMC Bioinformatics 2019; 20(Suppl 25): 689.
[http://dx.doi.org/10.1186/s12859-019-3263-x]
[20]
You J, McLeod RD, Hu P. Predicting drug-target interaction network using deep learning model. Comput Biol Chem 2019; 80: 90-101.
[http://dx.doi.org/10.1016/j.compbiolchem.2019.03.016] [PMID: 30939415]
[21]
Huang K, Xiao C, Glass LM, Sun J. MolTrans: Molecular Interaction Transformer for drug–target interaction prediction. Bioinformatics 2021; 37(6): 830-6.
[http://dx.doi.org/10.1093/bioinformatics/btaa880] [PMID: 33070179]
[22]
Vamathevan J, Clark D, Czodrowski P, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov 2019; 18(6): 463-77.
[http://dx.doi.org/10.1038/s41573-019-0024-5] [PMID: 30976107]
[23]
Wang Z, Liu M, Luo Y, et al. MoleculeKit: Machine learning methods for molecular property prediction and drug discovery. arXiv 2020.
[24]
Wang Z, Liu M, Luo Y, et al. Advanced graph and sequence neural networks for molecular property prediction and drug discovery. Bioinformatics 2022; 38(9): 2579-86.
[http://dx.doi.org/10.1093/bioinformatics/btac112] [PMID: 35179547]
[25]
Mouchlis VD, Afantitis A, Serra A, et al. Advances in De Novo Drug Design: From Conventional to Machine Learning Methods. Int J Mol Sci 2021; 22(4): 1676.
[http://dx.doi.org/10.3390/ijms22041676] [PMID: 33562347]
[26]
Madaj R, Geoffrey B, Sanker A, Valluri PP. Target2DeNovoDrug: A novel programmatic tool for in silico-deep learning based de novo drug design for any target of interest. J Biomol Struct Dyn 2021; 1-12.
[http://dx.doi.org/10.1080/07391102.2021.1898474] [PMID: 33703998]
[27]
Popova M, Isayev O, Tropsha A. Deep reinforcement learning for de novo drug design. Sci Adv 2018; 4(7): eaap7885.
[http://dx.doi.org/10.1126/sciadv.aap7885] [PMID: 30050984]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy